The Latest Analyst Ratings For Biogen
Portfolio Pulse from Benzinga Insights
Biogen (NASDAQ:BIIB) has received mixed analyst ratings over the past three months, with a recent decline in the average 12-month price target. Analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance. Biogen's financials show strong profitability and effective cost management, but its revenue growth lags behind industry peers.
October 10, 2024 | 9:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Biogen has received a mix of bullish and bearish analyst ratings, with a recent decline in the average 12-month price target. Analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance. Despite strong profitability, Biogen's revenue growth lags behind industry peers.
The article provides a detailed analysis of Biogen's recent analyst ratings, showing a mix of bullish and bearish perspectives. The average price target has declined, indicating a potential neutral impact on the stock price. Biogen's strong profitability is a positive factor, but its revenue growth lagging behind peers could be a concern for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100